{
  "ticker": "NUVL",
  "company_name": "Nuvalent, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05384626",
      "title": "A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Locally Advanced Solid Tumor, Metastatic Solid Tumor",
      "start_date": "2022-06-09",
      "completion_date": "2028-01",
      "enrollment": 0,
      "sponsor": "Nuvalent Inc."
    },
    {
      "nct_id": "NCT06765109",
      "title": "Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive",
      "start_date": "2025-07-17",
      "completion_date": "2029-12",
      "enrollment": 0,
      "sponsor": "Nuvalent Inc."
    },
    {
      "nct_id": "NCT06834074",
      "title": "Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors",
      "status": "AVAILABLE",
      "phase": "",
      "condition": "Non Small Cell Lung Cancer, ALK-positive Non-small Cell Lung Cancer (NSCLC)",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Nuvalent Inc."
    },
    {
      "nct_id": "NCT06521554",
      "title": "A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Locally Advanced Solid Tumor, Metastatic Solid Tumor",
      "start_date": "2024-07-18",
      "completion_date": "2026-03",
      "enrollment": 0,
      "sponsor": "Nuvalent Inc."
    },
    {
      "nct_id": "NCT05118789",
      "title": "A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Locally Advanced Solid Tumor, Metastatic Solid Tumor",
      "start_date": "2022-01-04",
      "completion_date": "2028-12-31",
      "enrollment": 0,
      "sponsor": "Nuvalent Inc."
    },
    {
      "nct_id": "NCT06797362",
      "title": "Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors",
      "status": "AVAILABLE",
      "phase": "",
      "condition": "Non Small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC)",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Nuvalent Inc."
    }
  ],
  "summary": {
    "total_trials": 6,
    "by_phase": {
      "PHASE1, PHASE2": 2,
      "PHASE3": 1,
      "": 2,
      "PHASE1": 1
    },
    "by_status": {
      "RECRUITING": 4,
      "AVAILABLE": 2
    },
    "active_trials": 4,
    "completed_trials": 0,
    "conditions": [
      "Locally Advanced Solid Tumor, Metastatic Solid Tumor",
      "Non Small Cell Lung Cancer, ALK-positive Non-small Cell Lung Cancer (NSCLC)",
      "Non Small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC)",
      "Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:20:24.993837",
    "search_query": "Nuvalent, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Nuvalent,+Inc."
  }
}